Astellas Pharma Inc. (FRA:YPH)

Astellas Pharma Statistics

Total Valuation

Astellas Pharma has a market cap or net worth of EUR 24.30 billion. The enterprise value is 26.89 billion.

Market Cap	24.30B
Enterprise Value	26.89B

Important Dates

The last earnings date was Wednesday, February 4, 2026.

Earnings Date	Feb 4, 2026
Ex-Dividend Date	Sep 29, 2025

Share Statistics

Current Share Class	1.79B
Shares Outstanding	n/a
Shares Change (YoY)	+0.64%
Shares Change (QoQ)	-0.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.79B

Valuation Ratios

The trailing PE ratio is 13.86.

PE Ratio	13.86
Forward PE	n/a
PS Ratio	2.17
PB Ratio	2.54
P/TBV Ratio	16.27
P/FCF Ratio	10.99
P/OCF Ratio	9.77
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.08, with an EV/FCF ratio of 12.16.

EV / Earnings	15.33
EV / Sales	2.38
EV / EBITDA	8.08
EV / EBIT	11.82
EV / FCF	12.16

Financial Position

The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.41.

Current Ratio	1.09
Quick Ratio	0.79
Debt / Equity	0.41
Debt / EBITDA	1.19
Debt / FCF	1.78
Interest Coverage	37.13

Financial Efficiency

Return on equity (ROE) is 19.82% and return on invested capital (ROIC) is 16.07%.

Return on Equity (ROE)	19.82%
Return on Assets (ROA)	7.38%
Return on Invested Capital (ROIC)	16.07%
Return on Capital Employed (ROCE)	18.28%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	820,466
Profits Per Employee	128,572
Employee Count	13,643
Asset Turnover	0.58
Inventory Turnover	1.27

Taxes

In the past 12 months, Astellas Pharma has paid 359.95 million in taxes.

Income Tax	359.95M
Effective Tax Rate	17.03%

Stock Price Statistics

The stock price has increased by +47.37% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+47.37%
50-Day Moving Average	11.92
200-Day Moving Average	9.70
Relative Strength Index (RSI)	62.72
Average Volume (20 Days)	165

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Astellas Pharma had revenue of EUR 11.19 billion and earned 1.75 billion in profits. Earnings per share was 0.97.

Revenue	11.19B
Gross Profit	9.07B
Operating Income	2.26B
Pretax Income	2.11B
Net Income	1.75B
EBITDA	3.31B
EBIT	2.26B
Earnings Per Share (EPS)	0.97

Balance Sheet

The company has 1.38 billion in cash and 3.94 billion in debt, with a net cash position of -2.56 billion.

Cash & Cash Equivalents	1.38B
Total Debt	3.94B
Net Cash	-2.56B
Net Cash Per Share	n/a
Equity (Book Value)	9.59B
Book Value Per Share	5.35
Working Capital	633.85M

Cash Flow

In the last 12 months, operating cash flow was 2.49 billion and capital expenditures -276.06 million, giving a free cash flow of 2.21 billion.

Operating Cash Flow	2.49B
Capital Expenditures	-276.06M
Free Cash Flow	2.21B
FCF Per Share	n/a

Margins

Gross margin is 81.00%, with operating and profit margins of 20.22% and 15.67%.

Gross Margin	81.00%
Operating Margin	20.22%
Pretax Margin	18.88%
Profit Margin	15.67%
EBITDA Margin	29.53%
EBIT Margin	20.22%
FCF Margin	19.75%

Dividends & Yields

This stock pays an annual dividend of 0.45, which amounts to a dividend yield of 3.34%.

Dividend Per Share	0.45
Dividend Yield	3.34%
Dividend Growth (YoY)	1.78%
Years of Dividend Growth	10
Payout Ratio	42.15%
Buyback Yield	-0.64%
Shareholder Yield	2.70%
Earnings Yield	7.22%
FCF Yield	9.10%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.

Last Split Date	Mar 27, 2014
Split Type	Forward
Split Ratio	5

Scores

Astellas Pharma has an Altman Z-Score of 2.24 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.24
Piotroski F-Score	7